Hillsdale Investment Management Inc. Halozyme Therapeutics, Inc. Transaction History
Hillsdale Investment Management Inc.
- $1.13 Billion
- Q2 2024
A detailed history of Hillsdale Investment Management Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Hillsdale Investment Management Inc. holds 108,400 shares of HALO stock, worth $6.2 Million. This represents 0.5% of its overall portfolio holdings.
Number of Shares
108,400
Previous 112,900
3.99%
Holding current value
$6.2 Million
Previous $4.59 Million
23.58%
% of portfolio
0.5%
Previous 0.41%
Shares
8 transactions
Others Institutions Holding HALO
# of Institutions
488Shares Held
122MCall Options Held
208KPut Options Held
66.3K-
Black Rock Inc. New York, NY17.6MShares$1.01 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$737 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$333 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$231 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$213 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.97B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...